interessant...

Basic research and drug trials under discussion at the NIH


In a recent interview,

Collins described the range of possibilities under discussion. “They’re talking about everything from basic science – the metabolome, microbiome, immune system, imaging – to clinical trials for promising approaches, including Ampligen and Rituximab,” Dr. Collins said.

http://www.meaction.net/2015/12/21/...-ampligen-and-rituximab-trials/

da liegt der Hund begraben :-))

The Company believes that this combination of a large compensation holdback coupled with the Executives' ability to recoup this amount and possibly more aligns the Executives' compensation to their performance and rewards them only if they are able to increase stockholder value and penalizes them if they fail to achieve the minimum floor stock price of $.20 per share for several successive days. This enhances the incentives related to improving the Company's business and raising its stock price.

https://biz.yahoo.com/e/160204/heb8-k.html